B-Cell Malignancies—Expert Guidance on BTK Inhibitors for Today’s Clinic

Join us for this dynamic, CME-certified “Evening with Experts” symposium where an expert panel led by Andrew D. Zelenetz, MD, PhD, will review the evolving role of BTK inhibitors in cancer treatment, including optimal current treatment across B-cell malignancies, management of related AEs, an update on the latest clinical data on BTK inhibitors, and future directions. Case discussions will help participants understand where BTK inhibitors can be integrated into clinical management along with standard-of-care therapies.

Can’t make it to Chicago on June 1, 2019? You can still participate through the live simulcast!

Sign up now! Registration is complimentary.

Sheraton Grand Chicago

Route 7 (Gate 21: North Bldg, level 1)

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.


Pre-registration is now closed. We welcome you to register on-site at the Sheraton Grand Chicago (301 E North Water Street), Sheraton Ballroom IV (Ballroom Level) at 6:30 PM. Remember to bring your ASCO Annual badge to expedite your registration.

6:30 PM – 7:00 PM  Dinner and Registration

7:00 PM – 7:10 PM  Program Overview Andrew D. Zelenetz, MD, PhD; Program Chair

7:10 PM – 7:40 PM  Case Discussions: Selecting BTK inhibitor Therapy in B-Cell Malignancies

7:40 PM – 8:10 PM  Case Discussions: Managing Adverse Events and Improving Adherence

8:10 PM – 8:40 PM  Near-Future Directions of BTK Inhibitor Therapy in B-Cell Malignancies

8:40 PM – 9:00 PM  Conclusions and Audience Question & Answer Session


Date / Time
Event Details


Program Chair
Andrew D. Zelenetz, MD, PhD

Medical Director, Quality Informatics
Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill-Cornell Medical College
New York, New York

John Byrd, Other

Distinguished University Professor 
D. Warren Brown Chair of Leukemia Research
Senior Adviser for Cancer Experimental Therapeutics
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Ian W. Flinn, MD, PhD

Director, Lymphoma Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Goal Statement
The goal of this activity is to improve participants’ competence in using BTK inhibitors to improve treatment outcomes for patients with B-cell malignancies.

Target Audience 
This program is intended for hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with MCL, CLL, and other B-cell malignancies.

Learning Objectives 

  • Evaluate differences among agents targeting BTK in terms of molecular characteristics, preclinical data, approved indications, dosing, safety profile, and efficacy
  • Consider existing and emerging clinical research data evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) in the formulation of therapeutic recommendations for patients with MCL, CLL, and other B-cell malignancies
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support quality of life and continuation of treatment
  • Explain to patients the importance of and provide strategies for optimal adherence to prescribed BTK inhibitors
  • Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) to aid clinical trial enrollment and predict new options in the clinic


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
CCO designates this live activity or enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.